Tags

Type your tag names separated by a space and hit enter

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Minerva Endocrinol. 2009 Dec; 34(4):333-8.ME

Abstract

The importance of renin-angiotensin aldosterone system (RAAS) in cardiovascular and renal diseases has long ago been recognized. However despite the availability of many effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, RAAS blockade is incomplete in several patients with consequent uncontrolled high blood pressure and not efficacy cardiovascular and renal protection. Aliskiren is a new renin inhibitor that block the RAAS at its origin. Recent studies suggest that Aliskiren reduces blood pressure, inhibits plasma renin activity and attenuates renal damage in diabetic patients with nephropathy. This review summarized the results of the more important studies performed in hypertensive and diabetic patients in which Aliskiren showed to be a safe and effective antihypertensive agent that can be used in monotherapy or in combination with other drugs to provide additional options to improve blood pressure control.

Authors+Show Affiliations

Cittadella General Hospital, Padua, Italy. dallav@libero.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20046162

Citation

Dalla Vestra, M, et al. "Aliskiren: a New Inhibitor of Renin-angiotensin Aldosterone System Activity." Minerva Endocrinologica, vol. 34, no. 4, 2009, pp. 333-8.
Dalla Vestra M, Simioni N, Masiero A. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Minerva Endocrinol. 2009;34(4):333-8.
Dalla Vestra, M., Simioni, N., & Masiero, A. (2009). Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Minerva Endocrinologica, 34(4), 333-8.
Dalla Vestra M, Simioni N, Masiero A. Aliskiren: a New Inhibitor of Renin-angiotensin Aldosterone System Activity. Minerva Endocrinol. 2009;34(4):333-8. PubMed PMID: 20046162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. AU - Dalla Vestra,M, AU - Simioni,N, AU - Masiero,A, PY - 2010/1/5/entrez PY - 2010/1/5/pubmed PY - 2010/5/12/medline SP - 333 EP - 8 JF - Minerva endocrinologica JO - Minerva Endocrinol VL - 34 IS - 4 N2 - The importance of renin-angiotensin aldosterone system (RAAS) in cardiovascular and renal diseases has long ago been recognized. However despite the availability of many effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, RAAS blockade is incomplete in several patients with consequent uncontrolled high blood pressure and not efficacy cardiovascular and renal protection. Aliskiren is a new renin inhibitor that block the RAAS at its origin. Recent studies suggest that Aliskiren reduces blood pressure, inhibits plasma renin activity and attenuates renal damage in diabetic patients with nephropathy. This review summarized the results of the more important studies performed in hypertensive and diabetic patients in which Aliskiren showed to be a safe and effective antihypertensive agent that can be used in monotherapy or in combination with other drugs to provide additional options to improve blood pressure control. SN - 0391-1977 UR - https://www.unboundmedicine.com/medline/citation/20046162/Aliskiren:_a_new_inhibitor_of_renin_angiotensin_aldosterone_system_activity_ L2 - http://www.minervamedica.it/index2.t?show=R07Y2009N04A0333 DB - PRIME DP - Unbound Medicine ER -